Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jul 15

PMID 35837384

Authors

Yuguo Zhang

Bolni Marius Nagalo

Affiliations

Soon will be listed here.

Abstract

Vesicular stomatitis virus (VSV), a negative-strand RNA virus of the genus, has demonstrated encouraging anti-neoplastic activity across multiple human cancer types. VSV is particularly attractive as an oncolytic agent because of its broad tropism, fast replication kinetics, and amenability to genetic manipulations. Furthermore, VSV-induced oncolysis can elicit a potent antitumor cytotoxic T-cell response to viral proteins and tumor-associated antigens, resulting in a long-lasting antitumor effect. Because of this multifaceted immunomodulatory property, VSV was investigated extensively as an immunovirotherapy alone or combined with other anticancer modalities, such as immune checkpoint blockade. Despite these recent opportunities to delineate synergistic and additive antitumor effects with existing anticancer therapies, FDA approval for the use of oncolytic VSV in humans has not yet been granted. This mini-review discusses factors that have prompted the use of VSV as an immunovirotherapy in human cancers and provides insights into future perspectives and research areas to improve VSV-based oncotherapy.

Citing Articles

A self-adjuvant multiantigenic nanovaccines simultaneously activate the antiviral and antitumor immunity for the treatment of cancers.

Wang Z, Chen H, Ming R, Wang W, Liu S, Jing Y J Nanobiotechnology. 2025; 23(1):150.

PMID: 40016753 PMC: 11866856. DOI: 10.1186/s12951-025-03208-1.

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Borella F, Carosso M, Chiparo M, Ferraioli D, Bertero L, Gallio N Pathogens. 2025; 14(2).

PMID: 40005517 PMC: 11858389. DOI: 10.3390/pathogens14020140.

Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.

Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E Biomedicines. 2025; 13(1).

PMID: 39857692 PMC: 11762644. DOI: 10.3390/biomedicines13010108.

Molecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs.

Ma Y, Shao J, Liu W, Gao S, Zhou G, Qi X Vet Sci. 2025; 12(1).

PMID: 39852910 PMC: 11769090. DOI: 10.3390/vetsci12010036.

SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis.

Chen F, Lang L, Yang J, Yang F, Tang S, Fu Z Biomark Res. 2025; 13(1):8.

PMID: 39789615 PMC: 11721257. DOI: 10.1186/s40364-025-00726-w.

References

Abdelmageed A, Ferran M . The Propagation, Quantification, and Storage of Vesicular Stomatitis Virus. Curr Protoc Microbiol. 2020; 58(1):e110. PMC: 7449588. DOI: 10.1002/cpmc.110. View

Hanson R . The natural history of vesicular stomatitis. Bacteriol Rev. 1952; 16(3):179-204. PMC: 180742. DOI: 10.1128/br.16.3.179-204.1952. View

Leveille S, Goulet M, Lichty B, Hiscott J . Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol. 2011; 85(23):12160-9. PMC: 3209377. DOI: 10.1128/JVI.05703-11. View

Hayek A, McCluskey B, Chavez G, Salman M . Financial impact of the 1995 outbreak of vesicular stomatitis on 16 beef ranches in Colorado. J Am Vet Med Assoc. 1998; 212(6):820-3. View

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

Durham N, Mulgrew K, McGlinchey K, Monks N, Ji H, Herbst R . Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Mol Ther. 2017; 25(8):1917-1932. PMC: 5542805. DOI: 10.1016/j.ymthe.2017.05.006. View

Muik A, Dold C, Geiss Y, Volk A, Werbizki M, Dietrich U . Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl). 2012; 90(8):959-70. PMC: 3396339. DOI: 10.1007/s00109-012-0863-6. View

Li J, Zhang L, Zhang J, Wei Y, Li K, Huang L . Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis. 2012; 34(3):658-66. DOI: 10.1093/carcin/bgs384. View

Roberts A, Kretzschmar E, Perkins A, Forman J, Price R, Buonocore L . Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol. 1998; 72(6):4704-11. PMC: 109996. DOI: 10.1128/JVI.72.6.4704-4711.1998. View

10.

Ahmed M, McKenzie M, Puckett S, Hojnacki M, Poliquin L, Lyles D . Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol. 2003; 77(8):4646-57. PMC: 152115. DOI: 10.1128/jvi.77.8.4646-4657.2003. View

11.

Mire C, Geisbert J, Agans K, Satterfield B, Versteeg K, Fritz E . Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One. 2014; 9(4):e94355. PMC: 3997383. DOI: 10.1371/journal.pone.0094355. View

12.

Bishnoi S, Tiwari R, Gupta S, Byrareddy S, Nayak D . Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses. 2018; 10(2). PMC: 5850397. DOI: 10.3390/v10020090. View

13.

Patterson W, MOTT L, Jenney E . A study of vesicular stomatitis in man. J Am Vet Med Assoc. 1958; 133(1):57-62. View

14.

Martuza R, Malick A, Markert J, Ruffner K, Coen D . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252(5007):854-6. DOI: 10.1126/science.1851332. View

15.

Duntsch C, Zhou Q, Jayakar H, Weimar J, Robertson J, Pfeffer L . Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model. J Neurosurg. 2004; 100(6):1049-59. DOI: 10.3171/jns.2004.100.6.1049. View

16.

Schnell M, Mebatsion T, Conzelmann K . Infectious rabies viruses from cloned cDNA. EMBO J. 1994; 13(18):4195-203. PMC: 395346. DOI: 10.1002/j.1460-2075.1994.tb06739.x. View

17.

Patel M, Jacobson B, Ji Y, Drees J, Tang S, Xiong K . Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget. 2015; 6(32):33165-77. PMC: 4741756. DOI: 10.18632/oncotarget.5320. View

18.

Pearl T, Markert J, Cassady K, Ghonime M . Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019; 13:14-21. PMC: 6453942. DOI: 10.1016/j.omto.2019.03.001. View

19.

Obuchi M, Fernandez M, Barber G . Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol. 2003; 77(16):8843-56. PMC: 167243. DOI: 10.1128/jvi.77.16.8843-8856.2003. View

20.

Ahmed M, Puckett S, Lyles D . Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther. 2010; 17(12):883-92. PMC: 3682428. DOI: 10.1038/cgt.2010.46. View